Twilight Venture Partners
Twilight Venture Partners is a venture capital firm dedicated to fostering early-stage life science companies, driving breakthroughs in biotechnology and medical technology with a strategic focus on the dynamic Asian market.
Investing in the Dawn of Life Science Innovation in Asia
At Twilight Venture Partners, we believe the most significant advancements in life sciences emerge from bold ideas and dedicated teams in their nascent stages. With a deep understanding of the biotechnology and medical technology sectors, and a keen eye on the burgeoning opportunities within Asia, we provide not just capital, but also strategic guidance and a global network to help visionary entrepreneurs bring their innovations to life. We are committed to partnering with companies that are poised to reshape healthcare and improve lives.
About Us
Our Vision: Illuminating the Future of Life Sciences
Twilight Venture Partners is an early-stage venture capital firm with a singular focus: to invest in and nurture groundbreaking life science companies. Our expertise lies within the biotechnology and medical technology sectors, where we seek out innovations with the potential for significant impact.
Recognizing the immense growth and potential within the Asian market, we have strategically shifted our focus to identify and support promising ventures in this dynamic region. We believe that the intersection of cutting-edge science and the vibrant Asian ecosystem offers unique opportunities for growth and global reach.
Our approach goes beyond simply providing funding. We strive to be true partners to the companies we invest in, offering our deep industry knowledge, extensive network, and strategic insights to help them navigate the complexities of early-stage development and achieve their full potential.
make an appointment
Have a Question for Us?
We are always eager to connect with visionary entrepreneurs, fellow investors, and industry leaders who share our passion for advancing life sciences. If you have an early-stage life science company with groundbreaking potential, or if you are interested in partnering with Twilight Venture Partners, we encourage you to reach out.
contact nowour portfolio
Pioneering Ventures: Our Investments
We are proud to partner with a diverse range of early-stage companies that are at the forefront of life science innovation. Our portfolio reflects our commitment to supporting transformative technologies in biotechnology and medical technology, with an increasing emphasis on ventures within the Asian market.
MBX Biosciences
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients.
NeoChord
regurgitation due to leaflet prolapse. The company's tool is used for conducting a minimally invasive procedure when the native Chordae Tendinae have become elongated or ruptured, while the heart is beating and bypasses the need for conducting cardiopulmonary bypass or aortic cross-clamping, enabling surgeons to stop the leakage of blood backward through the mitral valve in patients suffering from mitral regurgitation.
Nico
Developer of minimally invasive surgical devices designed to be used in neurosurgery. The company combines patented technologies within an integrated systems approach of imaging and intervention to help hospitals and hospitals and neurosurgeons provide minimally disruptive brain surgery to patients, enabling healthcare providers to improve patient outcomes.
BioStorage Technologies
Provider of sample-management services for the bioscience sector.The company manages the complete life cycle of samples, using a team of global sample experts, temperature-controlled storage facilities and a real-time, Web-based sample intelligence and tracking system. It operates biostorage facilities in the U.S. state of Indiana and Frankfurt, Germany.
Wap Guro
Using advanced artificial intelligence technology to help traditional Chinese medicine doctors improve diagnostic accuracy, optimize treatment plans, inherit ancient wisdom, and create a new chapter in the modernization of traditional Chinese medicine.
We are committed to providing our portfolio companies with the strategic guidance and support they need to navigate the challenges of early-stage growth and achieve their long-term objectives.
about our team
Our Expertise: Guiding Innovation
The Twilight Venture Partners team brings together a wealth of experience in life sciences, venture capital, and global business. We are passionate about supporting early-stage companies and leveraging our collective expertise to help them succeed.
Aaron Pearson
Managing Partner
Aaron Pearson is the Managing Partner at Twilight Venture Partners, bringing to the firm a distinguished career marked by deep expertise in life sciences and a proven track record in venture capital. With decades of experience navigating the complexities of the biotechnology and medical technology sectors, Aaron possesses a wealth of knowledge in identifying and nurturing early-stage companies with transformative potential. His strategic acumen, coupled with an extensive network within the global life science ecosystem, particularly in the burgeoning Asian market, makes him an invaluable asset to the firm and its portfolio companies. Aaron's insightful leadership and commitment to fostering innovation drive Twilight Venture Partners' mission to support the next generation of life science breakthroughs. His profound understanding of scientific advancements, coupled with his keen business sense, provides portfolio companies with invaluable guidance in navigating the challenges and opportunities of growth.
Kent Hawryluk
Partner
experience and a profound understanding of the life science investment landscape. 1 His career spans significant tenures in both scientific research and venture capital, providing him with a unique and comprehensive perspective on identifying promising early-stage ventures. Kent's deep knowledge of biotechnology and medical technology, coupled with his strategic insights into market dynamics, particularly within the rapidly evolving Asian market, allows him to provide invaluable guidance to portfolio companies. His meticulous approach to due diligence and his ability to recognize groundbreaking science with commercial potential have been instrumental in the success of numerous ventures. Kent's commitment to fostering innovation and his extensive network within the scientific and investment communities make him a key driver in Twilight Venture Partners' mission to support transformative life science companies.
contact us
Let's Connect: Partnering for Innovation
We are always eager to connect with visionary entrepreneurs, fellow investors, and industry leaders who share our passion for advancing life sciences. If you have an early-stage life science company with groundbreaking potential, or if you are interested in partnering with Twilight Venture Partners, we encourage you to reach out.
Recent Biotechnology News Globally
Global Biotechnology Insights: Staying Ahead of Innovation
Keeping abreast of the latest developments in the global biotechnology landscape is crucial for informed investment decisions. Here are some recent headlines highlighting the rapid advancements and key trends shaping the industry worldwide
(Bullet Points of Recent News - Based on the provided search results from April 2025)
April 8
2025
Research indicates that the entire rotavirus genome, not just surface proteins, influences vaccine effectiveness.
April 8
2025
Scientists discover a natural compound in fruits and vegetables that may slow the progression of ALS and dementia.
April 4
2025
A novel genomic screening tool is developed, enabling precise reverse-engineering of genetic programming in cells.
April 4
2025
Researchers describe how cells with defective mitochondria activate a special recycling system.
April 3
2025
Study reveals how common gut bacteria can metabolize certain oral medications, potentially reducing their effectiveness.
April 2
2025
Analysis of the flowerpot snake's genome provides insights into DNA repair and mutation prevention.
March 27
2025
Scientists achieve detailed inner ear imaging without surgery using terahertz radiation.
March 27
2025
Engineered peptides from frog skin show promise as new antibiotics against resistant bacteria.
March 26
2025
Japanese researchers successfully rewrite the rules of primate genetic engineering using a nonviral system.
March 19
2025
Scientists detect "electric spiking" communication in skin cells for the first time.